Neoscytalidium dimidiatum as onychomycosis causative agent in an Iranian patient: a case report and literature review

T. Razavyyoon1, S. J. Hashemi1, S. Ansari1, P. Mansouri1, R. Daie-Ghavzini1, S. Khodavaisy1, Z. Rafat4, H. Kamali Sarvestani1, L. Hosseinpour1, P. Afshar5, F. Hashemi6 and F. safaie7

1) Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, 2) Department of Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, 3) Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, 4) Department of Medical Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, 5) Research and Development of Referral Laboratory, Deputy of Health Management, Mazandaran University of Medical Sciences, Sari, 6) School of Pharmacy, Tehran University of Medical Sciences and 7) Islamic Azad University, Tehran Medical Branch, Iran

Abstract

A 38-year-old healthy male presented to our medical mycology center with whitish opaque discoloration of the right toenail. He reported a history of some sand scratches subsequent to walking barefoot on the beach two years ago and wearing hard safety shoes for a period of two years. On clinical examination, onycholysis, onychodystrophy, and apparent thickening of the ungual bed in the left big toe were found. The microscopic examination of nail clippings using 15% potassium hydroxide (KOH/) revealed the presence of septate pigmented hyphae. The fungus was identified as Neoscytalidium dimidiatum based on the cultural characteristics, the arrangement of arthroconidia on lactophenol cotton blue (LPCB) staining, blocky-brown pigmented hyphae on serum physiology mounts, and sequencing. Susceptibility of the isolated fungi to amphotericin B, itraconazole, voriconazole, and terbinafine was tested using the standard broth microdilution M38-A2 method developed by the Clinical and Laboratory Standards Institute (CLSI). The minimum inhibitory concentrations (MICs) of the four antifungal drugs used in this study were: amphotericin B: 1 mg/L, itraconazole: 2 mg/L, voriconazole: 0.25 mg/L, and terbinafine: 1 mg/L. The patient underwent terbinafine and clobetasol topical treatments for 6 months.

Keywords: Iran, Neoscytalidium dimidiatum, Onychomycosis, Antifungal susceptibility testing, Sequencing

Introduction

Onychomycosis is a term that refers to all nail disorders caused by fungal etiologic agents with a prevalence of 18–40% of all onychopathies [1]. The main types of onychomycosis have been described as distal and lateral subungal onychomycosis, superficial white onychomycosis, proximal subungal onychomycosis, endonyx onychomycosis, and total dystrophic onychomycosis [2,3]. Etiologic agents of onychomycosis mostly consist of three different groups of fungi; dermatophyte, molds, and yeasts. The prevalence of etiologic fungi varies and depends on different factors like sex, age, occupation, climate, health situation, cultural habits, country, geographic (urban and rural) area, underlying disease, and diagnostic evaluation methods [3]. Saprophytic fungi divided into hyaline and dematiaceous fungi. Dematiaceous or black refers to melanin-producing yeasts, yeast-likes, and filamentous fungi. Mostly they live in soil and plants. Several of those can cause disease in humans and animals with a spectrum of superficial mycosis to severe encephalitis [4]. Neoscytalidium sp. (formerly: Scytalidium) are ascomycetous fungi belong to a large and heterogeneous group of fungi that cause Phaeohyphomycosis. Some though can infect humans via direct contact, sometimes traumatic, with colonized plants or vegetable residues [5]. Neoscytalidium dimidiatum and its hyaline...
mutant, *N. dimidiatum* var. *hyalinum* can cause clinical lesions in nail and skin similar to those produced by dermatophytes [6]. Here, we report the case of a 38-year-old man with onychomycosis caused by *N. dimidiatum* in Iran.

**Case report**

A 38-year-old electrical engineer male presented to our medical mycology center with whitish opaque discoloration of the right toenail for a duration of two years. His medical history showed some sand scratches subsequent to walking barefoot on the beach two years ago and wearing hard safety shoes for a period of two years. Also, his medical reports showed that his allergic rhinitis due to concha surgery (nose flesh surgery) had been under control. Furthermore, the laboratory reports showed negative results for viral hepatic tests (HBC-Ab and HIV-Ab, HBs-Ab > 400 mIU/mL) and normal results for routine laboratory tests. On clinical examination, onycholysis and onychodystrophy, with apparent thickening of ungual bed in the left big toe were found (Fig 1: A). He underwent terbinafine and clobetasol topical treatments after initial diagnosis using potassium hydroxide (KOH) smear (Fig 2) and culture. No evidence of progress in treatment was seen. With the rest of the nail clipping, the second culture was conducted about two months later of the first visit. The microscopic examination of nail scrapings using 15% KOH revealed the presence of septate hyaline hyphae. The material was cultured on Sabouraud’s dextrose agar (SDA) with and without cycloheximide and cornmeal agar. The SDA without cycloheximide grew woolly brown colonies after seven days of incubation at room temperature. There was no growth on SDA with cycloheximide. Greyish black colonies grew on SDA (Fig. 3: A&B). Normal saline mounts showed numerous cylindrical or globose, one-to-two-celled barrel-shaped arthroconidia with dark walls and many wide and septate brown and hyaline hyphae (Fig 4). The fungus was identified as *Neoscytalidium* sp. based on the cultural characteristics, the arrangement of arthroconidia on lactophenol cotton blue (LPCB) staining, and dark hyphae on serum physiology mounts. Accurate identification was accomplished via sequencing analysis. Briefly, genomic DNA was isolated from fresh colonies using a method described previously [7]. Then, PCR was carried out bilaterally to amplify the ITS regions of the rDNA gene using the pan fungal primers: ITS1 (5’TCCGTAAGTTAACCCGCGG-3’) and ITS4 (5’-TCCTCCGCTTAAGATATGC-3’) [8]. The amplicon was sent for sequencing, which showed 100% similarity with the sequence of *Neoscytalidium dimidiatum* clone URF_Pt01 (accession number MT010216) deposited in NCBI BLAST (https://www.blast.ncbi.nlm.nih.gov/Blast.cgi) database. The relevant sequence extracted from current study (*Neoscytalidium dimidiatum*) has been deposited in GenBank under accession number MZ377100. The in-vitro antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) document M38-A2 method [10]. The minimum inhibitory concentrations (MICs), the result of the four antifungal drugs used in the study were: amphotericin B: 1 mg/L, itraconazole: 2 mg/L, voriconazole: 0.25 mg/L, and terbinafine: 1 mg/L. The treatment has changed to itraconazole 100 mg/day and amorolfin nail lacquer for 10 weeks subsequently. Drug tolerance was well and toenail infected areas were reduced (Fig. 1B). Written informed consent was obtained from the patient. All data were de-identified. This Health Insurance Portability and Accountability Act–compliant study received approval from the institutional review board (IR.TUMS.SPH.REC.1398.197).
Discussion

Onychomycosis challenges such as aesthetic problems, difficulty in running or rotating, and more make discomfort situations for patients. Causative agents of onychomycosis include molds, dermatophytes, and yeasts [35]. Studies demonstrate that the prevalence and distribution of causative agents of onychomycosis can vary according to geographic location, climate, and cultural customs [11,35]. Non-dermatophyte molds (NDMs) are one of the etiologic agents of onychomycosis which divided into hyaline and dematiaceous fungi. The most common hyaline NDMs are different species of *Aspergillus*, *Scopulariopsis*, *Alternaria*, *Acremonium*, and *Fusarium* [12–14]. *A. flavus* and *A. niger* complex are generally isolated from abnormal nails [15], but there are also reports of onychomycosis due to rare species of *Aspergillus* like *A. candidum* [16] or *A. sydowii* [15].

Among dematiaceous NDMs *Cyphellophora* and *Phialophora* are involved in onychomycosis and mild skin infections [4]. Also, *Neoscytalidium* sp. is a genus of dematiaceous fungi that has been isolated from several nail infections [11]. *N. dimidiatum* and its mutant *N. hyalinum* can both play a similar role in causing onychomycosis or superficial skin infections and are clinically indistinguishable from dermatophytosis. *N. dimidiatum* more commonly invade the nails, toe tissues, and soles of the feet with hyperkeratosis; however, hands are rarely affected [17]. The fungi first inhabit toenails by a laterodistal development. Paronychia may also occur as total nail dystrophy. Palm lesions are mainly unilateral although single affecting is classically bilateral reproducing the two-foot one-hand syndrome [6,17–19].

*Neoscytalidium* infections have a different prevalence in the world that it seems is more dependent on the geographic area than the susceptible population. Mostly there are two clinical forms of *Neoscytalidium* infections in published articles, onychomycosis, and systemic disease [20]. A systematic review conducted on NDMs etiologic agents of onychomycosis in 2012 among nine countries (Canada, Colombia, Spain, Italy, Greece, Pakistan, Thailand, and Brazil) shows that 4% of onychomycosis etiologic agent belong to *N. dimidiatum* which occurred only in the study conducted in Brazil and none in the other countries contribute in the article [13]. In São Paulo, Brazil from 588 cases of onychomycosis, NDMs were isolated in 7.4% of positive cultures related to toenail onychomycosis with 2.3% *Natrassia mangiferae* (*Neoscytalidium*) [21]. Furthermore, in Alagoas, Brazil during 2009-2016 only 0.1 percent of each annual sampling refers to *Neoscytalidium* sp. [22]. One report from Thailand showed *Fusarium* and *Scytalidium dimidiatum* are two major etiologic agents of onychomycosis due to NDMs.
Deep infection in scytalidiosis is mostly accompanied by immune suppression in situations like lung and renal transplant, diabetes, or further underlying disease. There are several reports about profound infection as central nervous system abscesses, endophthalmitis, sinusitis, osteomyelitis mycetoma, subcutaneous lesions, and disseminated infection caused by Neoscytalidium sp. \[22,24–31\]. N. dimidiatum is involved more than N. hyalinum in deep mycosis \[32\] and its related mortality is about 50% \[17\]. A study from Iran presented a fatal case of Nattrassia mangiferae (Neoscytalidium sp.) encephalitis after thorn eye penetration in a diabetic 60-year-old male with cirrhosis and heart failure \[33\]. In another study, a cerebral phaeohyphomycosis due to Nattrassia mangiferae (Neoscytalidium sp.) reported in Iran. This case was a 17-year-old male with a history of systemic lupus erythematos and renal involvement. The diagnosis was based on histopathologic and mycologic evidence after craniotomy \[27\]. In onychomycosis, oral drugs in combination with nail lacquer should offer better results than single treatment with antifungals \[5\]. A professional removal of the infected area along with antifungal therapy is recommended as a perfect therapeutic method \[34\]. Also, several case reports had assessed in vitro antifungal susceptibility testing of different antifungal agents against Neoscytalidium sp. isolated from clinical specimens (Table 1).

Diagnosis of onychomycosis is challenging and it starts by the rollout of other dermatology disorders which can affect healthy nail appearance. After reaching fungal etiology, there are some differential diagnosis criteria that differ molds from dermatophytes like priority of skin involvement than the nail, infection in more than one nail in dermatophytes, and other practical evidence. But historically, scytalidiosis was distinguished from dermatophytic onychomycosis by resistance to routine antidermatophyte treatments. It is notable that clinically differentiate between scytalidiosis and dermatophytosis is unintelligible \[7\]. The primary diagnosis of onychomycosis is based on potassium hydroxide (KOH) smear and culture. In NDMs diagnosis in comparison to dermatophytes and yeasts diagnosis, there is a need to more evaluations such as identification of the NDM in the nail by microscopy (KOH preparation), culture isolation, repeated isolation in culture, inoculum counting, failure to isolate a dermatophyte in culture, and histology. \[13\]. The most reliable methods are molecular approaches such as PCR-sequencing for molds and also Neoscytalidium. Although it is uncommon due to special equipment and experience. Furthermore, the results achieved with mass analysis through

**TABLE 1.** Case reports demonstrated in vitro antifungal susceptibility testing of different antifungal agents against Neoscytalidium sp.

| Reference            | Case No | Country      | Sex/Age | Infection site       | Treatment                                                      | Diagnosis                  |
|----------------------|---------|--------------|---------|----------------------|----------------------------------------------------------------|----------------------------|
| Garinet et al. \[36\]/2001 | 1       | French Guyana | M/53    | Leg & toenail         | Surgical, oral itraconazole, and local amphotericin B           | Neoscytalidium sp.          |
| Garinet et al. \[36\]/2002 | 2       | Ivory coast  | F/64    | Sole & nail of feet   | Local terbinfine                                                 | N. hyalinum                |
| Jabbarvand \[37\]/2004 | 3       | Iran         | M/32    | Eye                  | Natamycin eyedrop and oral ketoconazole                         | Neoscytalidium sp.          |
| Geramishoar \[37\]/2004 | 4       | Iran         | M/17    | Soft tissue (cranal abases) | Corticosteroid and cyclophosphamide                          | Neoscytalidium sp.          |
| Sadeghi Tai \[37\]/2005 | 5       | Iran         | M/60    | Eye                  | Surgery & systemic imipenem, metronidazole, and amphotericin B with | Neoscytalidium sp.          |
| Garinet \[36\]/2007 | 6       | Mauritania   | M/52    | Ankle                | Surgical, oral terbinafine, and local amphotericin B            | N. dimidiatum               |
| Elnar \[37\]/2009 | 7       | Israel       | M/56    | Lung and pleura       | Intravenous voriconazole and Amphotericin B from intra pleural root | N. dimidiatum               |
| Garinet \[36\]/2011 | 8       | Cameroon     | M/59    | Leg & foot            | Oral voriconazole and topical ketoconazole                      | N. dimidiatum               |
| Garinet \[36\]/2011 | 9       | Congo        | M/59    | Elbow, back, and leg  | Oral voriconazole                                                | N. dimidiatum               |
| Roy \[39\]/2013 | 10      | India        | NA/55   | Toenails             | Oral itraconazole                                                | Neoscytalidium sp.          |
| Dionne \[38\]/2015 | 11      | USA          | M/50    | Lung                 | Amphotericin B, posaconazole                                    | N. dimidiatum               |
| Shokoohi et al. \[39\]/2020 | 12    | Iran         | F/52    | Finger nail          | Oral terbinafine plus ciclopirox nail lacquer                   | N. novohollande               |
| Present case/2021 | 13      | Iran         | M/38    | Toe nail             | Oral terbinafine then changed to itraconazole and ciclopirox lacquer | N. dimidiatum               |

**Abbreviations:** M: male; F: Female; Neoscytalidium sp.: not molecular base diagnosis; NA: not available.
dendrogram construction of MALDI-TOF MS of *N. dimidiatum* showed valuable and cost-effective assessed with ITS rDNA gene analysis technics [28].

In conclusion, to the best of our knowledge, the present case is the first report of onychomycosis caused by *N. dimidiatum* in Iran. The precise identification of etiologic agents of onychomycosis and antifungal susceptibility testing before antifungal treatment is necessary.

**Transparency declaration**

Authors declare no conflicts of interest.

Informed permission was attained for experimentation with human subjects.

**Acknowledgments**

This study was supported by funding from Tehran University of Medical Sciences (Grant number: 640).

**References**

[1] André J, Rigopoulos D, Elewski B, Richert B. Histopathology of onychomycosis. Onychomycosis Diagn Eff Manag 2018;1:60–5.
[2] Zaias N. Onychomycosis. Arch Dermatol 1972;105:263–74.
[3] Baran R, Hay RJ, Tosti A, Hanek E. A new classification of onychomycosis. Br J Dermatol 1998;139:567–71.
[4] Chowdhary A, Perfect J, de Hoog GS. Black molds and melanized yeasts pathogenic to humans. Cold Spring Harb Perspect Med 2015;5: a019570.
[5] Avner S, Nir N, Henri T. Combination of oral terbina- and topical ciclopirox compared to oral terbina- and antifungal agents. Human Press; 2012. p. 65.
[6] Ford T, Dyer T, Lewis T, Taylor J. Amplification of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013;5:2571–81.
[7] Godoy-Martinez P, Nunes FG, Tomimori-Yamashita J, Urrutia M, Zaro L, Silva V, Fischman O. Onychomycosis in São Paulo, Brazil. Mycopathologia 2009;168:11–6.
[8] de Albuquerque Maranhão FC, Oliveira-Júnior JB, dos Santos Araújo MA, Silva DM. Mycoses in northeastern Brazil: epidemiology and prevalence of fungal species in 8 years of retrospective analysis in Alagoas. Braz J Microbiol 2019;50:969–78.
[9] Ungsukorn R, Loharprathan S, Reangchainam S. Prevalence of foot diseases in outpatients attending the Institute of Dermatology, Bangkok, Thailand. Clin Exp Dermatol Viewpoints Dermatol 2004;29: 87–90.
[10] Sigler L, Summerbell RC, Poole L, Wieden M, Sutton DA, Rinaldi MG. Aguirre M, Estes GW, Galgiani JN. Invasive Nattrassia mangiferae in- fections: case report, literature review, and therapeutic and taxonomic appraisal. J Clin Microbiol 1997;35(2):433–40.
[11] White T, Taylor J, Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. PCR Protoc A Guide Methods Appl 1990;18:315–22.
[12] Noorbakhsh F, Gheramishoar M, Rezaie S. A case of onychomycosis and scytalidiosis: what’s new in 2012? J Mycol Med 2013:30:100920.
[13] Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans antifungal resistance. J Clin Microbiol 2013;51:2571–81.
[14] English MP, Atkinson R. Onychomycosis in elderly chiropody patients. Br J Dermatol 1984;110:677–83.
[15] Ellis DH, Watson AB, Marley JE, Williams TG. Non-dermatophyte onychomycosis of the toenails. Br J Dermatol 1997;136:490–3.
[16] Machouart M, Menir P, Helenon R, Quénéhervé C, Cals-Quist D, Garsaud P. Onychomycoses à Scytalidium en Martinique. In: Annales de dermatologie et de vénéréologie, vol. 131. Elsevier Masson; 2004. p. 245–9.
[17] Hay RJ, Moore MK. Clinical features of superficial fungal infections caused by Hendersonula toruloidea and Scytalidium hyalurn. Br J Dermatol 1984;110:677–83.
[18] Ellis DH, Watson AB, Marley JE, Williams TG. Non-dermatophyte onychomycosis of the toenails. Br J Dermatol 1997;136:490–3.
[19] Godoy-Martinez P, Nunes FG, Tomimori-Yamashita J, Urrutia M, Zaro L, Silva V, Fischman O. Onychomycosis in São Paulo, Brazil. Mycopathologia 2009;168:11–6.
[20] de Albuquerque Maranhão FC, Oliveira-Júnior JB, dos Santos Araújo MA, Silva DM. Mycoses in northeastern Brazil: epidemiology and prevalence of fungal species in 8 years of retrospective analysis in Alagoas. Braz J Microbiol 2019;50:969–78.
[21] Ungsukorn R, Loharprathan S, Reangchainam S. Prevalence of foot diseases in outpatients attending the Institute of Dermatology, Bangkok, Thailand. Clin Exp Dermatol Viewpoints Dermatol 2004;29: 87–90.
[22] Sigler L, Summerbell RC, Poole L, Wieden M, Sutton DA, Rinaldi MG, Aguirre M, Estes GW, Galgiani JN. Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal. J Clin Microbiol 1997;35(2):433–40.
[23] Pfeifer MA, Messer SA, Woosley LN, Jones RN, Castanheira M, Perfect J, Lewis T, Taylor J. Amplification of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013;51:2571–81.
[24] Gumbo T, Mkangani N, Robertson VJ, Masvaire P. Case report.
[25] Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013;51:2571–81.
[26] Gumbo T, Mkangani N, Robertson VJ, Masvaire P. Case report.
[27] Geramishoar M, Zomorodian K, Zaini F, Saadat F, Tarazooie B, Norouzi M, Rezaie S. First case of cerebral phaeohyphomycosis caused by Nattrassia mangiferae in Iran. Jpn J Infect Dis 2004;57:285–6.
[28] Manuel A, Chickabizahia YT, Nagarathna S, Chandramuki A, Shippakarak MR, Vijayan J, Prasanthan DK, Vasudevan PS, Natarajan A, Kovoor J. Cerebral phaeohyphomycosis caused by Scytalidium dit- idium: a case report from India. Med Mycol 2008;46:285–92.
[29] Banik RS, Chickabizahia YT, Nagarathna S, Chandramuki A, Shippakarak MR, Vijayan J, Prasanthan DK, Vasudevan PS, Natarajan A, Kovoor J. Cerebral phaeohyphomycosis caused by Scytalidium dit- idium: a case report from India. Med Mycol 2008;46:285–92.
[30] Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003;47: 2404–12.
[31] Elinav H, Izhar U, Benenson S, Admon D, Hidalgo-Grass C, Polacheck I, Korem M. Invasive Scytalidium dimidiatum infection in an immunocompetent adult. J Clin Microbiol 2009;47(4):1259–63.

[32] Zaatari GS, Reed R, Morewessel R. Subcutaneous hyphomycosis caused by Scytalidium hyalinum. Am J Clin Pathol 1984;82:252–6.

[33] Tari AS, Mardani M, Rahnavardi M, Amoli FA, Abedinifar Z. Post-traumatic fatal Nattrassia mangiferae orbital infection. Int Ophthalmol 2005;26:247–50.

[34] Malay DS, Yi S, Borowsky P, Downey MS, Mlodzien ski AJ. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J Foot Ankle Surg 2009;48(3):294–308.

[35] Rafat Z, Hashemi SJ, Saboor-Yaraghi AA, Pouraghha B, Taheri niyas A, Moosavi A, et al. A systematic review and meta-analysis on the epidemiology, casual agents and demographic characteristics of onychomycosis in Iran. J Mycol Med 2019;29:265–72.

[36] Garinet S, Tourret J, Barete S, Arzouk N, Meyer I, Frances C, Darty A, Mazier D, Barrou B, Fekkar A. Invasive cutaneous Neoscytalidium infections in renal transplant recipients: a series of five cases. Invasive cutaneous Neoscytalidium infections in renal transplant recipients: a series of five cases. BMC Infect Dis 2015;15(535):1–7.

[37] Jabbarvand M, Hashemian MR, Abedinifar Z, Amini A. Nattrassia mangiferae keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2004;30(1):268–72.

[38] Dionne B, Neff L, Lee SA, Sutton DA, Wiederhold NP, Lindner J, Fan H, Jakeman B. Pulmonary fungal infection caused by Neoscytalidium dimidiatum. J Clin Microbiol 2015;53:2381–4.

[39] Roy P, Bhatt P. Nattrassia mangiferae: an uncommon agent of onychomycosis. Med J Armed Forces India 2015;71:297–9.